- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Licensing fees boost Sonus’ Q4 profits
Ultrasound contrast agent developer Sonus Pharmaceuticals reported $3 million in net income for the fourth quarter of 1999 (end-December), due primarily to a second $5 million licensing payment from Nycomed Amersham. Bothell, WA-based Sonus entered into
Ultrasound contrast agent developer Sonus Pharmaceuticals reported $3 million in net income for the fourth quarter of 1999 (end-December), due primarily to a second $5 million licensing payment from Nycomed Amersham. Bothell, WA-based Sonus entered into a $10 million patent cross-licensing agreement with Nycomed last September (SCAN 10/13/99). That agreement helped Sonus year-end results considerably as well; the company reported revenues of $12 million for 1999, compared to $5 million in 1998. Net income for the year was $400,000, compared to a net loss of $11.2 million for 1998. Sonus is currently awaiting FDA clearance for EchoGen, its first ultrasound contrast agent, which the company already sells in Europe.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
